Literature DB >> 19811439

Effects of the CCR5-Delta32 mutation on hepatitis C virus-specific immune responses in patients with haemophilia.

Golo Ahlenstiel1, Rainer P Woitas, Agathe Iwan, Jacob Nattermann, Georg Feldmann, Jürgen K Rockstroh, Johannes Oldenburg, Bernd Kupfer, Tilman Sauerbruch, Ulrich Spengler.   

Abstract

In hepatitis C virus (HCV) infection antiviral T cells express the CC chemokine receptor 5 (CCR5). Their recruitment to the liver is an important step in the immune response. A 32 base pair deletion in the CCR5 gene leads to reduced expression and total loss of CCR5 in CCR5-Delta32 heterozygous and homozygous subjects, respectively. However, the role of this mutation for antiviral immunity remains unclear. Here, we analysed proliferation, IFN-gamma and IL-4 secretion (ELISpot) induced by the HCV antigens core, NS3, NS4, and NS5a in 21 anti-HCV-positive haemophiliac patients in relationship to their CCR5 genotypes (CCR5 wildtype n = 10, CCR5-Delta32 heterozygous n = 5 and CCR5-Delta32 homozygous n = 6). Furthermore, T cell migration in response to the CCR5 ligands CCL3, -4 and -5 was studied. Overall IFN-gamma responses to HCV proteins were only slightly greater in CCR5 wild-type patients than in CCR5-Delta32 carriers (0.6 versus 0.24 SFC/10(4) PBMC; p = 0.043). This difference was consistently seen with all tested HCV antigens. In contrast, neither T cell migration, nor PBMC proliferation, nor IL-4 production differed between CCR5 genotypes. Interruption of the CCR5 signalling pathway due to CCR5-Delta32 may potentially result in subtle reduction of HCV specific IFN-gamma responses in anti-HCV-positive haemophiliac patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19811439     DOI: 10.1080/08820130902832035

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  4 in total

1.  Effects of the Chemokine Receptor 5 (CCR5)-Delta32 Mutation on Hepatitis C Virus-Specific Immune Responses and Liver Tissue Pathology in HCV Infected Patients.

Authors:  Abdulkerim Yilmaz; Hakan Alagozlu; Ozturk Ozdemir; Sema Arici
Journal:  Hepat Mon       Date:  2014-07-01       Impact factor: 0.660

2.  A Study on the Association between CCRΔ32 Mutation and HCV Infection in Iranian Patients.

Authors:  Farahnaz Bineshian; Asieh Hosseini; Zohre Sharifi; Afsaneh Aghaie
Journal:  Avicenna J Med Biotechnol       Date:  2018 Oct-Dec

Review 3.  Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases.

Authors:  Joel Henrique Ellwanger; Bruna Kulmann-Leal; Valéria de Lima Kaminski; Andressa Gonçalves Rodrigues; Marcelo Alves de Souza Bragatte; José Artur Bogo Chies
Journal:  Virus Res       Date:  2020-05-30       Impact factor: 3.303

4.  CCR5 receptor antagonism inhibits hepatitis C virus (HCV) replication in vitro.

Authors:  Jason T Blackard; Ling Kong; Susan D Rouster; Rebekah Karns; Paul S Horn; Shyam Kottilil; M Tarek Shata; Kenneth E Sherman
Journal:  PLoS One       Date:  2019-10-29       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.